In terms of cost, Invokana also doesn't have a generic option, which means you'll be paying about the same price for this drug if you don't have insurance. Some commercial insurers and Medicare Part D ...

J&J says Invokana is the only oral diabetes treatment to reduce the risk of these cardiovascular events and is hoping that the new indication will help reverse a steep slide in sales of the drug ...

Invokana was the first SGLT2 inhibitor to reach ... product was linked to an increased risk of lower limb amputation. The drug promptly went into reverse, with sales coming in at $738 million ...